Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.
Foà R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, Ferrara F, Lunghi M, Mulè A, Bonifacio M, Fracchiolla N, Salutari P, Fazi P, Guarini A, Rambaldi A, Chiaretti S. Foà R, et al. Among authors: mule a. J Clin Oncol. 2024 Mar 10;42(8):881-885. doi: 10.1200/JCO.23.01075. Epub 2023 Dec 21. J Clin Oncol. 2024. PMID: 38127722 Free PMC article.
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study.
Lazzarotto D, Tanasi I, Vitale A, Piccini M, Dargenio M, Giglio F, Forghieri F, Fracchiolla N, Cerrano M, Todisco E, Papayannidis C, Leoncin M, Defina M, Guolo F, Pasciolla C, Delia M, Chiusolo P, Mulè A, Candoni A, Bonifacio M, Pizzolo G, Foà R. Lazzarotto D, et al. Among authors: mule a. Ann Hematol. 2023 May;102(5):1099-1109. doi: 10.1007/s00277-023-05162-0. Epub 2023 Mar 24. Ann Hematol. 2023. PMID: 36959485
Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.
Cardinali D, Beldinanzi M, Ansuinelli M, Elia L, Della Starza I, Bellomarino V, Matarazzo M, Di Trani M, Cola M, Salutari P, Cedrone M, Bassan R, De Gobbi M, Della Porta MG, De Simone M, Alati C, Fracchiolla NS, Lunghi M, Intermesoli T, Cardinali V, Mulè A, Guarini A, Foà R, Chiaretti S. Cardinali D, et al. Among authors: mule a. Leuk Lymphoma. 2023 Nov-Dec;64(11):1884-1887. doi: 10.1080/10428194.2023.2235450. Epub 2023 Jul 15. Leuk Lymphoma. 2023. PMID: 37452789 No abstract available.
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study.
Malfona F, Tanasi I, Piccini M, Papayannidis C, Federico V, Mancini V, Roncoroni E, Todisco E, Bianchi S, Ciotti G, Chiusolo P, Gentile M, Gianfelici V, Giglio F, Malagola M, Mulé A, Saraceni F, Vetro C, Zallio F, Cappelli LV, Pizzolo G, Foà R, Bonifacio M, Chiaretti S. Malfona F, et al. Among authors: mule a. Haematologica. 2024 Mar 1;109(3):988-993. doi: 10.3324/haematol.2023.283684. Haematologica. 2024. PMID: 37794811 Free PMC article. No abstract available.
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial.
Venditti A, Piciocchi A, Candoni A, Arena V, Palmieri R, Filì C, Carella AM, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Curti A, Luppi M, Ingrosso C, Martelli MP, Cuneo A, Albano F, Mulè A, Tafuri A, Cudillo L, Tieghi A, Fracchiolla NS, Capelli D, Trisolini SM, Alati C, La Sala E, Maurillo L, Del Principe MI, Irno Consalvo MA, Divona MD, Ottone T, Cerretti R, Sconocchia G, Voso MT, Fazi P, Vignetti M, Buccisano F. Venditti A, et al. Among authors: mule a. Blood Adv. 2024 Aug 27;8(16):4410-4413. doi: 10.1182/bloodadvances.2024013182. Blood Adv. 2024. PMID: 38968139 Free PMC article. No abstract available.
[No title available]
[No authors listed] [No authors listed] PMID: 39112353
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study.
Lazzarotto D, Cerrano M, Papayannidis C, Chiaretti S, Mosna F, Fracchiolla N, Zappasodi P, Imbergamo S, Del Principe MI, Lunghi M, Lussana F, Piccini M, Fumagalli M, Dargenio M, Salutari P, Forghieri F, Da Molin TG, Bonifacio M, Olivi M, Giglio F, Trappolini S, Leoncin M, Mule A, Delia M, Pasciolla C, Grimaldi F, Cambo B, Santoro L, Guolo F, Minetto P, Defina M, Chiusolo P, Fanin M, Mauro E, Aprile L, Mazzone C, Trastulli F, Ciccone M, De Gobbi M, Cignetti A, De Bellis E, Mancini V, Piciocchi A, Vignetti M, Marsili G, Starza ID, Fanin R, Luppi M, Ferrara F, Pizzolo G, Bassan R, Foa R, Candoni A. Lazzarotto D, et al. Among authors: mule a. Haematologica. 2024 Aug 15. doi: 10.3324/haematol.2024.285638. Online ahead of print. Haematologica. 2024. PMID: 39157875 Free article.
Sorafenib maintenance after allogeneic stem cell transplantation in patients with FLT3+ AML receiving midostaurin during induction and consolidation: a retrospective analysis.
Sapienza G, Castronovo M, Tringali S, Bono R, Rotolo C, Mulè A, Calafiore V, Patti C, Agueli C, Randazzo V, Santoro A, Matranga D, Castagna L. Sapienza G, et al. Among authors: mule a. Front Oncol. 2024 Sep 19;14:1441254. doi: 10.3389/fonc.2024.1441254. eCollection 2024. Front Oncol. 2024. PMID: 39364317 Free PMC article.
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
Leotta S, Markovic U, Duminuco A, Mulè A, Porretto F, Federico V, Gentile M, Pastore D, Nigro LL, Selleri C, Serio B, Calafiore V, Patti C, Mauro E, Vetro C, Maugeri C, Parisi M, Fiumara P, Parrinello L, Marino S, Scuderi G, Garibaldi B, Musso M, Renzo ND, Vigna E, Martino EA, Raimondo FD, Milone G. Leotta S, et al. Among authors: mule a. Ann Hematol. 2024 Sep;103(9):3701-3712. doi: 10.1007/s00277-024-05725-9. Epub 2024 Apr 13. Ann Hematol. 2024. PMID: 38609726
239 results